LKFT

distress 1/10 · well-funded / low risk

$28.14-2%today-25% from 52w high

lakefrontbio.com452 employeesFounded 1999Mechelen, BelgiumBiotechnology

Revenue

pre-revenue

Liquidity

$3030M

Runway

11.8 yrs

Shares 1y

Price & events

-18.2% over 6M

CatalystRating changeDilutionFinancingdashed = today

-2.2%

-4.9%

-3.1%

-1.9%

-18.2%

-15.5%

+3.4%

-53.0%

-71.6%

All

Overview

Market Cap: $1.85B
Volume: 27.48K
52 Week Range: $26.61 – $37.62
Total Shares: 65.90M
Float Shares: 818.81M
Short %: 5.56%
% Held by Insiders: 25.35%
% Held by Institutions: 22.64%
RVOL: 0.17x
Beta: 0.12

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 1

2026-08-10earningsEarningsEarnings releaseyahoo

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 65,897,071 · 1 offerings/1y · 0 PIPEs

2026-05-08424B3offering
2024-11-12SC 13G/Astrategic_stake
2024-10-08SC 13D/Astrategic_stake
2024-08-23SC 13Dstrategic_stake

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

hold · target $25 (-10% upside) · 3 analysts

2026-02-25RBC CapitalSector Perform

Competitors

none identified